• α-Bungarotoxin: Mapping α7 Receptor Causality

  2026-08-29

  α-Bungarotoxin enables precise nicotinic receptor blockade for testing α7 nAChR-dependent signaling. This article explains how its use in pyridostigmine-treated placental ischemia models strengthens causal assay design beyond simple pathway observation.

• HyperScript III RT SuperMix for CRC qPCR

  2026-08-29

  Translate bile acid metabolism signatures into reproducible CRC biomarker assays with high-yield cDNA synthesis, integrated genomic DNA contamination removal, and support for difficult RNA templates. The workflow is designed for low-abundance, high-GC, and low-copy transcripts measured by SYBR Green or probe-based qPCR.

• Cy5-UTP (Cyanine 5-UTP) Workflow Guide

  2026-08-28

  Learn how Cy5-UTP (Cyanine 5-UTP), SKU B8333, can strengthen RNA probe synthesis, fluorescence in situ hybridization, and fluorescence-assisted cell assay workflows. This scenario-based guide separates RNA labeling from viability measurement and provides practical guidance on compatibility, optimization, interpretation, and vendor selection.

• Protein A/G Magnetic Co-IP/IP Kit Workflow

  2026-08-28

  Turn antibody-based capture into a reproducible workflow for protein complex isolation, ubiquitination studies, and antibody purification. The Protein A/G Magnetic Co-IP/IP Kit combines Fc region antibody binding with rapid magnetic separation for downstream SDS-PAGE or mass spectrometry.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-08-27

  Fabi and Malaguti’s 2013 review evaluated palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for preventing radio- and chemotherapy-induced nausea and vomiting. Its central contribution was to clarify why high receptor affinity and prolonged half-life may improve delayed control, particularly after moderately emetogenic chemotherapy, while identifying unresolved needs in multi-day treatment and combination antiemetic therapy.

• BIRC2 and BIRC3 Regulation in Pulmonary Epithelium

  2026-08-27

  Thorne et al. define distinct responses of BIRC2 and BIRC3 to inflammatory cytokines and glucocorticoids in pulmonary epithelial models. Their multi-model design shows that BIRC3 is strongly inducible and potentially protective, whereas BIRC2 is comparatively constitutive, providing a framework for interpreting epithelial inflammatory signaling and cell-death resistance.

• Guanabenz Acetate: A Layered Assay Strategy

  2026-08-26

  Guanabenz Acetate enables a layered approach to α2-adrenergic receptor pharmacology, separating receptor-proximal signaling from stress-granule and innate-immune phenotypes. This article translates recent GADD34–IRF3 findings into practical, hypothesis-driven assay decisions.

• Drug Response Metrics in Cancer In Vitro

  2026-08-26

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measurements capture different relationships between proliferative arrest and cell death. The framework supports more informative in vitro drug-response experiments by requiring researchers to interpret growth inhibition and killing as related but noninterchangeable outcomes.

• PexRAP Links Ether Lipids to B-Cell Immunity

  2026-08-25

  Cho and colleagues show that B-lineage expression of the ether-lipid biosynthesis enzyme PexRAP, encoded by Dhrs7b, supports B-cell survival, germinal center development, antibody production, and affinity maturation. By combining inducible mouse genetics, imaging mass spectrometry, immunization, and mechanistic cell assays, the study connects cell-intrinsic lipid metabolism with the quality of humoral immunity.

• Amikacin Sulfate: NTM Assay Workflows

  2026-08-25

  Build stronger non-tuberculous mycobacterial studies by connecting extracellular CFU testing, intracellular dendritic-cell assays, and granuloma-level pharmacology. This workflow also adapts the functional-selection logic of a Cas9 inhibitor discovery study without confusing a metagenomic screening principle with antibiotic evidence.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-24

  The PKH26 Red Fluorescent Cell Linker Kit provides stable red labeling of cell-membrane lipid regions for longitudinal tracing and proliferation-oriented assays. It is intended for membrane labeling in vitro or in vivo, not for intracellular targets, organelles, or other non-membrane applications.

• Palomid 529 (P529): PI3K/Akt/mTOR Research Guide

  2026-08-23

  Palomid 529, also called P529, is a dual mTORC1 and mTORC2 inhibitor for pathway-focused cancer research. Product information reports activity against NCI-60 tumor cells, VEGF- and bFGF-stimulated endothelial proliferation, and radiation-associated angiogenic markers, while direct validation in ESCC remains an open experimental question.

• Molidustat (BAY85-3934) Experimental Workflows

  2026-08-22

  Molidustat (BAY85-3934) enables controlled hypoxia-inducible factor stabilization for studying erythropoietin stimulation, renal anemia therapy, and oxygen-sensing biology. This guide translates HIF-PH inhibition into practical cell, biochemical, and translational workflows while addressing assay-specific pitfalls.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-08-21

  Turn ferroptosis and cytotoxicity experiments into rapid, quantitative viability measurements with a sensitive ATP-luminescence workflow. The assay is especially useful for low-density cultures, combination screens, and mechanistic studies where fast endpoint selection can reveal treatment-dependent cell loss.

• Imipenem: From PBP Assay to Resistance Map

  2026-08-21

  Imipenem can serve as more than a broad-spectrum antibacterial agent: it is a mechanistic anchor for linking PBP activity, carbapenemase genetics, plasmid mobility, and host-response experiments. This article presents an evidence-aligned framework for antibacterial research and preclinical assay design.

447 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page